[Paper-level Aggregated] PMCID: PMC11272140

Evidence Type(s): Oncogenic

Summary: Mutation: G2032R | Summary: The G2032R mutation contributes to tumor development or progression in the context of ROS1+ non-small cell lung cancer and is identified as a ROS1 resistance mutation in crizotinib-pretreated patients, suggesting its role in tumor progression and resistance to therapy.

Evidence Type: Oncogenic Mutation: L2026M | Summary: The L2026M mutation is noted as a ROS1 resistance mutation in crizotinib-pretreated patients, contributing to tumor development and resistance.

Evidence Type: Oncogenic Mutation: S1986F | Summary: The S1986F mutation is classified as a ROS1 resistance mutation in crizotinib-pretreated patients, suggesting its involvement in tumor progression and resistance mechanisms.

Evidence Type: Oncogenic Mutation: G2101A | Summary: The G2101A mutation, detected in a patient with crizotinib resistance, is implicated in tumor development and progression as a ROS1 resistance mutation.

Gene→Variant (gene-first): ROS1(6098):G2032R TXK(7294):L2026M TXK(7294):S1986F NTRK1(4914):G2101A

Genes: ROS1(6098) TXK(7294) NTRK1(4914)

Variants: G2032R L2026M S1986F G2101A

[Paper-level Aggregated] PMCID: PMC11272140

Evidence Type(s): Predictive

Summary: Mutation: G2032R | Summary: The G2032R mutation is associated with a favorable response to taletrectinib, indicating a predictive value for treatment response in ROS1+ non-small cell lung cancer, with a response rate of 67% in patients. Additionally, it is linked to acquired resistance to therapy, highlighting its relevance in predicting treatment outcomes and sensitivity to taletrectinib.

Gene→Variant (gene-first): ROS1(6098):G2032R

Genes: ROS1(6098)

Variants: G2032R

[Paragraph-level] PMCID: PMC11272140 Section: RESULTS PassageIndex: 10

Evidence Type(s): Oncogenic

Summary: Evidence Type: Oncogenic | Mutation: G2032R | Summary: The G2032R mutation is identified as a ROS1 resistance mutation in crizotinib-pretreated patients, indicating its role in tumor progression and resistance to therapy. Evidence Type: Oncogenic | Mutation: L2026M | Summary: The L2026M mutation is also noted as a ROS1 resistance mutation in crizotinib-pretreated patients, contributing to tumor development and resistance. Evidence Type: Oncogenic | Mutation: S1986F | Summary: The S1986F mutation is classified as a ROS1 resistance mutation in crizotinib-pretreated patients, suggesting its involvement in tumor progression and resistance mechanisms. Evidence Type: Oncogenic | Mutation: G2101A | Summary: The G2101A mutation, detected in a patient with crizotinib resistance, is implicated in tumor development and progression as a ROS1 resistance mutation.

Gene→Variant (gene-first): 6098:G2032R 4914:G2101A 7294:L2026M 7294:S1986F

Genes: 6098 4914 7294

Variants: G2032R G2101A L2026M S1986F

[Paragraph-level] PMCID: PMC11272140 Section: ABSTRACT PassageIndex: 8

Evidence Type(s): Predictive, Oncogenic

Summary: Evidence Type: Predictive | Mutation: G2032R | Summary: The G2032R mutation is associated with acquired resistance to therapy, indicating its relevance in predicting treatment response and sensitivity to taletrectinib. Evidence Type: Oncogenic | Mutation: G2032R | Summary: The G2032R mutation is mentioned in the context of acquired resistance mutations, suggesting its role in tumor development or progression.

Gene→Variant (gene-first): 6098:G2032R

Genes: 6098

Variants: G2032R

[Paragraph-level] PMCID: PMC11272140 Section: ABSTRACT PassageIndex: 6

Evidence Type(s): Predictive, Oncogenic

Summary: Evidence Type: Predictive | Mutation: G2032R | Summary: The G2032R mutation is associated with a response rate of 67% in patients, indicating its potential predictive value for treatment outcomes. Evidence Type: Oncogenic | Mutation: G2032R | Summary: The presence of the G2032R mutation suggests a role in tumor development or progression, as it is linked to patient responses in a cancer treatment context.

Gene→Variant (gene-first): 6098:G2032R

Genes: 6098

Variants: G2032R

[Paragraph-level] PMCID: PMC11272140 Section: ABSTRACT PassageIndex: 2

Evidence Type(s): Predictive, Oncogenic

Summary: Evidence Type: Predictive | Mutation: G2032R | Summary: The G2032R mutation is associated with a favorable response to taletrectinib, a ROS1 tyrosine kinase inhibitor, indicating its predictive value for treatment response in ROS1+ non-small cell lung cancer. Evidence Type: Oncogenic | Mutation: G2032R | Summary: The G2032R mutation contributes to tumor development or progression in the context of ROS1+ non-small cell lung cancer, supporting its classification as an oncogenic variant.

Gene→Variant (gene-first): 6098:G2032R

Genes: 6098

Variants: G2032R

[Paper-level Aggregated] PMCID: PMC11272140

Evidence Type(s): Oncogenic, Prognostic, Functional

Justification: Oncogenic: The G2032R mutation is associated with acquired resistance to crizotinib and is shown to respond to taletrectinib, indicating its role in cancer progression. Prognostic: The response rates and progression-free survival data for patients with G2032R mutations suggest that this variant can provide prognostic information regarding treatment outcomes with taletrectinib. Functional: The text indicates that taletrectinib has activity against the G2032R mutation, suggesting that this variant has functional implications in the context of treatment response.

Gene→Variant (gene-first): ROS1(6098):G2032R NTRK1(4914):G2101A TXK(7294):L2026M TXK(7294):S1986F

Genes: ROS1(6098) NTRK1(4914) TXK(7294)

Variants: G2032R G2101A L2026M S1986F

[Paragraph-level] PMCID: PMC11272140 Section: RESULTS PassageIndex: 10

Evidence Type(s): Predictive, Oncogenic

Justification: Predictive: The passage discusses the overall response rate (ORR) of patients with specific ROS1 mutations, including G2032R, in relation to treatment with taletrectinib, indicating a correlation with treatment response. Oncogenic: The presence of ROS1 resistance mutations, including G2032R, L2026M, S1986F, and G2101A, suggests that these somatic variants contribute to tumor development or progression, particularly in the context of resistance to crizotinib.

Gene→Variant (gene-first): 6098:G2032R 4914:G2101A 7294:L2026M 7294:S1986F

Genes: 6098 4914 7294

Variants: G2032R G2101A L2026M S1986F

[Paragraph-level] PMCID: PMC11272140 Section: ABSTRACT PassageIndex: 8

Evidence Type(s): Predictive, Oncogenic

Justification: Predictive: The passage discusses the variant G2032R in the context of acquired resistance mutations and mentions the overall responses and prolonged progression-free survival (PFS) associated with taletrectinib, indicating a correlation with treatment response. Oncogenic: The mention of G2032R as an acquired resistance mutation suggests that it contributes to tumor development or progression, particularly in the context of therapy resistance.

Gene→Variant (gene-first): 6098:G2032R

Genes: 6098

Variants: G2032R

[Paragraph-level] PMCID: PMC11272140 Section: ABSTRACT PassageIndex: 6

Evidence Type(s): Predictive

Justification: Predictive: The passage indicates that 67% of patients with G2032R mutations responded to treatment, suggesting a correlation between the variant and treatment response.

Gene→Variant (gene-first): 6098:G2032R

Genes: 6098

Variants: G2032R

[Paragraph-level] PMCID: PMC11272140 Section: ABSTRACT PassageIndex: 2

Evidence Type(s): Predictive, Oncogenic

Justification: Predictive: The passage discusses the activity of taletrectinib against the G2032R variant, highlighting its correlation with high response rates and prolonged progression-free survival, indicating predictive evidence related to therapy response. Oncogenic: The mention of the G2032R variant in the context of ROS1+ non-small cell lung cancer suggests that it may contribute to tumor development or progression, aligning with oncogenic evidence.

Gene→Variant (gene-first): 6098:G2032R

Genes: 6098

Variants: G2032R

[Paragraph-level] PMCID: PMC11272140 Section: ABSTRACT PassageIndex: 8

Evidence Type(s): Predictive, Oncogenic

Justification: Predictive: The passage discusses the variant G2032R in the context of acquired resistance mutations and mentions the overall responses and prolonged progression-free survival (PFS) associated with taletrectinib, indicating a correlation with treatment response. Oncogenic: The mention of G2032R as an acquired resistance mutation suggests that it contributes to tumor development or progression, particularly in the context of therapy resistance.

Gene→Variant (gene-first): 6098:G2032R

Genes: 6098

Variants: G2032R

[Paragraph-level] PMCID: PMC11272140 Section: ABSTRACT PassageIndex: 6

Evidence Type(s): Predictive

Justification: Predictive: The passage indicates that 67% of patients with G2032R mutations responded to treatment, suggesting a correlation between the variant and treatment response.

Gene→Variant (gene-first): 6098:G2032R

Genes: 6098

Variants: G2032R

[Paragraph-level] PMCID: PMC11272140 Section: ABSTRACT PassageIndex: 2

Evidence Type(s): Predictive, Oncogenic

Justification: Predictive: The passage discusses the activity of taletrectinib against the G2032R variant, highlighting its correlation with high response rates and prolonged progression-free survival, indicating predictive evidence related to therapy response. Oncogenic: The mention of the G2032R variant in the context of ROS1+ non-small cell lung cancer suggests that it may contribute to tumor development or progression, aligning with oncogenic evidence.

Gene→Variant (gene-first): 6098:G2032R

Genes: 6098

Variants: G2032R